Production (Stage)
Moleculin Biotech, Inc.
MBRX
$0.67
-$0.0201-2.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -29.50% | 81.67% | -88.84% | 27.73% | 37.21% |
| Total Depreciation and Amortization | -3.13% | -11.43% | 3.23% | 0.00% | 6.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 232.90% | -301.51% | 694.93% | -363.91% | -163.64% |
| Change in Net Operating Assets | 176.32% | -67.45% | 121.41% | -220.11% | -275.86% |
| Cash from Operations | 32.05% | -3.80% | 19.04% | -16.06% | -11.63% |
| Capital Expenditure | -- | 100.00% | 100.00% | 13.33% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 100.00% | 13.33% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -99.97% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 75.00% | -19.05% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -99.97% | 116,575.00% | -151.02% | -- |
| Foreign Exchange rate Adjustments | 133.33% | -650.00% | 240.00% | 900.00% | -125.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 151.12% | -398.25% | 81.04% | -17.40% | -14.39% |